ABBN.SW: $86.28 ▲ 0.18 (0.21%)ASML.AS: $1,563.20 ▲ 2.40 (0.15%)ENR.DE: $160.36 ▼ -2.14 (-1.32%)GLEN.L: $536.50 ▲ 1.20 (0.22%)IFX.DE: $81.41 ▲ 0.85 (1.06%)NOKIA.HE: $12.17 ▲ 0.17 (1.38%)RIO.L: $7,291.00 ▲ 27.00 (0.37%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Anebulo Pharmaceuticals, Inc.

ANEB - NASDAQ

Identifiants & Marche

Ticker ANEB
ISIN US0345691036
CIK 0001815974
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.